The role of apoptosis in the pathogenesis and treatment of diseases

European Respiratory Journal

Volumn 9, Issue 6, 1996, Pages 1293-1305

  Solary, E ^a   Dubrez, L ^a   Eymin, B ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Apoptosis; diseases; pathogenesis; treatment

Indexed keywords

AURINTRICARBOXYLIC ACID; CYSTEINE PROTEINASE; DNA FRAGMENT; DNA TOPOISOMERASE; FAS ANTIGEN; INTERLEUKIN 1BETA CONVERTING ENZYME; ONCOPROTEIN; PROTEIN P53; ZINC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; AUTOIMMUNITY; CELL DEATH; DEGENERATIVE DISEASE; DISEASE COURSE; ETIOLOGY; HEMATOLOGIC DISEASE; MALIGNANT TRANSFORMATION; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; VIRUS LATENCY;

ADULT; APOPTOSIS; DISEASE; HUMANS;

EID: 0030016233     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.96.09061293     Document Type: Review

References (152)

1. Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumour cell lines by widely divergent stimuli. Cell Prolif 1991 ; 24: 203-214.
2. Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR. Haematopoietic colony-stimulating factors promote cell survival by suppressing apoptosis. Nature 1990; 343: 76-79.
3. Crompton T. IL-3-dependent cells die by apoptosis on removal of their growth factor. Growth Factors 1991; 4: 109-116.
4. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed cell death in erythroid progenitor cells. Science 1990; 248: 371-378.
5. Stresser A. Death of a T-cell. Nature 1995; 373: 385-386.
6. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69: 119-128.
7. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-810.
8. Solary E, Bertrand R, Pommier Y. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. Blood 1993; 81: 1359-1368.
9. Raff MC. Social controls on cell survival and cell death. Nature 1992; 356: 397-400.
10. Boudreau N, Sympson CJ, Werb Z, Bissell MJ. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995; 267: 891-893.
11. Manabe A, Coustan-Smith E, Behm FG, Raimondi SC, Campana D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood 1992; 79: 2370-2377.
12. Hengartner MO, Horvitz HR. Programmed cell death in Caenorhabditis elegans. Curr Opin Gen Dev 1994; 4: 581-586.
13. Martin SJ, Green DR. Protease activation during apoptosis: death by a thousand cuts. Cell 1995; 82: 349-352.
14. Gagliardini V, Fernandez PA, Lee RKK, et al Prevention of vertebrate neuronal death by the crmA gene. Science 1994; 263: 826.
15. Hengartner MO, Horvitz HR. C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 1994; 76: 665-676.
16. Arends MJ, Wyllie AH. Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol 1991; 32: 223-254.
17. Zhivotovski B, Wade D, Nicotera P, Orrenius S. Role of nucleases in apoptosis. Int Arch Allergy Appl Immunol 1994; 105: 333-338.
18. Earnshaw WC. Nuclear changes in apoptosis. Curr Opin Cell Biol 1995; 7: 337-343.
19. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose)polymerase by a proteinase with properties like ICE. Nature 1994; 371: 346-347.
20. Li CJ, Friedman DJ, Wang C, Metelev V, Pardee AB. Induction of apoptosis in uninfected lymphocytes by HIV-1 tat protein. Science 1995; 268: 429-431.
21. Jensen PH, Cressey LI, Gjertsen BT, et al. Cleaved intracellular plasminogen activator inhibitor 2 in human myeloleukaemia cells is a marker of apoptosis. Br J Cancer 1994; 70: 834-840.
22. Wyllie AH, Rose KA, Morris RG, Stell CM, Forster E, Spandidis DA. Rodent fibroblast tumors expressing human myc and ras genes: growth, metastasis and endogenous oncogene expression. Br J Cancer 1987; 56: 251-259.
23. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes hematopoietic cell survival and co-operates with c-myc to immortalize pre-B cells. Nature 1992; 335: 440-442.
24. Reed JC. Bcl-2 and the regulation of cell death. J Cell Biol 1994; 124: 1-6.
25. Allsopp TE, Wyatt S, Paterson HF, Davies AM. The proto-oncogene bcl-2 can selectively rescue neurotrophic factor-dependent neurons from apoptosis. Cell 1993; 73: 295-307.
26. Levine B, Huang Q, Isaacs JT, Reed JC, Griffin DE, Hardwick JM. Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature 1993; 361: 739-742.
27. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151-157.
28. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and box in gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-1805.
29. Harris CC, Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Engl J Med 1993; 329: 1318-1327.
30. Kamb A. Sun protection factor p53. Nature 1994; 372: 730-731.
31. Kastan MB, Zhan Q, el-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia telangectasia. Cell 1992; 71: 587-597.
32. Ziegler A, Jonason AS, Leffel DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 773-776.
33. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell 1993; 74: 609-619.
34. Wyllie AH. Death gets a brake. Nature 1994; 369: 272-273.
35. Boise LH, Gonzales-Garcia M, Postema CE, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
36. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL-1, a gene expressed in programed myeloid cell differentiation, has sequence similarity to Bcl-2. Proc Natl Acad Sci USA 1993; 90: 3516-3520.
37. Kiefer MC, Brauer MJ, Powers VC, et al. Modulation of apoptosis by the widely distributed Bcl-2 homolog Bak. Nature 1995; 374: 736-739.
38. Chittenden T, Harrington EA, O'Connor R, et al. Induction of apoptosis by the Bcl-2 homolog Bak. Nature 1995; 374: 733-736.
39. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285-291.
40. Takayama S, Sato T, Krajewski S, et al. Cloning and functional analysis of BAG-1: a novel Bcl-2 binding protein with anti-cell death activity. Cell 1995; 80: 279-284.
41. Sato T, Hanada M, Bodrug S, et al. Interactions among members of the Bcl-2 protein family analyzed with a two-yeast hybrid system. Proc Natl Acad Sci USA 1994; 91: 9238-9242.
42. Evans CA, Owen-Lynch PJ, Whetton AD, Dive C. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. Cancer Res 1993; 53: 1735-1738.
43. McGahon AR, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83: 1179-1187.
44. Kagi D, Ledermann B, Bürki K, et al. Cytotoxicity mediated by T-cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369: 31-37.
45. Ray CA, Black RA, Kronheim SR, et al. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1β converting enzyme. Cell 1992; 69: 597-604.
46. Enari M, Hug H, Nagata S. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 1995; 375: 78-81.
47. Los M, Van de Craen M, Penning LC, et al. Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature 1995; 375: 81-83.
48. Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E. The adenovirus E1A proteins induce apoptosis which is inhibited by the E1B 19K and Bcl-2 proteins. Proc Natl Acad Sci USA 1992; 89: 7742-7746.
49. Henderson S, Huen D, Rowe M, Dawson C, Johnson G, Rickinson A. Epstein-Barr virus-coded BHRF1 protein, a viral homolog of Bcl-2, protects human B-cells from programmed cell death. Proc Natl Acad Sci USA 1993; 90: 8479-8483.
50. Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects B cells from programmed cell death. Cell 1991; 65: 1107-1115.
51. Roy N, Mahadevan MS, McLean M, et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 1995; 80: 167-178.
52. Mannick JB, Asano K, Izumi K, Kieff E, Stamler JS. Nitric oxide produced by human B-lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 1994; 79: 1137-1146.
53. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994; 152: 3685-3692.
54. 2+ channels exposed to serum from patients with type I diabetes. Science 1993; 261: 86-90.
55. Garchon HJ, Luan JJ, Eloy L, Bedossa P, Bach JF. Genetic analysis of immune dysfunction in nonobese diabetic (NOD) mice: mapping of a susceptibility locus close to the Bcl-2 gene correlates with increased resistance of NOD T-cells to apoptosis induction. Eur J Immunol 1994; 24: 380-384.
56. Stresser A, Whittingham S, Vaux DL, et al. Enforced Bcl-2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 1991; 88: 8661-8665.
57. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-317.
58. Roths JB, Murphy ED, Eicher EM. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J Exp Med 1984; 159: 1-20.
59. Nagata S, Goldstein P. The Fas death factor. Science 1995; 267: 1449-1456.
60. Suda T, Takahashi T, Goldstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
61. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233-243
62. Sato T, Irie S, Kitida S, Reed JC. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995; 168: 411-415.
63. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VML. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505-512.
64. Stanger BZ, Leder P, Lee TH, Kim E, Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 1995; 81: 513-523.
65. Boldin MP, Varfolomeev EE, Pancer Z, Mett L, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to death domain. J Biol Chem 1995; 270: 7795-7798.
66. Cifone MG, De Maria R, Roncaioli P, et al. Apoptotic signaling through CD95 (Fas/APO-1) activates an acidic sphingomyelinase. J Exp Med 1994; 180: 1547-1552.
67. Dhein J, Walczak H, Baümler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-l/(Fas/ CD95). Nature 1995; 373: 438-441.
68. Ju ST, Panka DJ, Cui H, et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995; 373: 444-448.
69. Berke G. The CTL's kiss of death. Cell 1995; 81: 9-12.
70. Watson M, Roa JK, Gilkeson GS, et al. Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J Exp Med 1992; 176: 1645-1656.
71. Fischer GH, Rosenberg FJ, Straus SE, et al. Crosslinking CD4 by human immunodeficiency virus gp120 primes T-cells for activation-induced apoptosis. J Exp Med 1992; 176: 1099-1106.
72. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268: 1347-1349.
73. Lenardo MJ, Puck JM. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81: 935-936.
74. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-1762.
75. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995; 14: 1129-1135.
76. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806-809.
77. Ando S, Hirabayashi Y, Kon K, Inagaki F, Tate S, Whittaker VP. A trisialoganglioside containing a sialyl alpha 2-6 N-acetylgalactosamine residue is a cholinergic-specific antigen, Chol-1 alpha. J Biochem 1992; 111: 287-290.
78. Ni R, Tomita Y, Matsuda K, et al. Fas-mediated apoptosis in primary cultured mouse hepatocytes. Exp Cell Res 1994; 215: 332-337.
79. Hiramatsu N, Hayashi N, Katayama K, et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994; 19: 1354-1359.
80. Meyaard L, Otto SA, Keet IP, Roos MT, Miedema F. Programmed death of T-cells in human immunodeficiency virus infection: no correlation with progression to disease. J Clin Invest 1994; 93: 982-988.
81. Banda NK, Bernier J, Kurahara DK, et al. Crosslinking CD4 by human immunodeficiency virus gp120 primes T-cells for activation-induced apoptosis. J Exp Med 1992; 176: 1099-1106.
82. Westendorp MO, Frank R, Ochsenbauer C, et al. Sensitization of T-cells to CD95-mediated apoptosis by HIV-1 tat and gp120. Nature 1995; 375: 497-500.
83. Katsikis PD, Wunderlich ES, Smith CA, Herzenberg LA. Fas antigen stimulation induces marked apoptosis of T-lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med 1995; 181: 2029-2036.
84. Leno M, Simpson RM, Bowers FS, Kindt TJ. Human T-lymphocyte virus 1 from a leukemogenic cell line mediates in vivo and in vitro lymphocyte apoptosis. J Exp Med 1995; 181: 1575-1580.
85. Cohen DA, Fitzpatrick EA, Barve SS, et al. Activation dependent apoptosis in CD4+ T-cells during murine AIDS. Cell Immunol 1993; 151: 392-402.
86. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990; 144: 3602-3610.
87. Yoshida Y. Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia 1993; 7: 144-146.
88. Clark DM, Lampert IA. Apoptosis is a common histopathological finding in myelodysplastic syndrome: the correlate of ineffective hemopoiesis. Leuk Lymphoma 1990; 2: 415-418.
89. Yuan J, Angelucci E, Lucarelli G, et al. Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe ß-thalassemia (Cooley's anemia). Blood 1993; 82: 374-377.
90. Choi DW. Excitotoxic cell death. J Neurobiol 1992; 23: 1261-1276.
91. Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, Cotman CW. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA 1993; 90: 7951-7955.
92. Edwards SN, Buckmaster AE, Tolkovsky AM. The death program in cultured sympathetic neurones can be suppressed at the post-translational level by nerve growth factor, cyclic AMP, and depolarization. J Neurochem 1991; 57: 2140-2143.
93. Barres BA, Hart IK, Coles HSR, et al. Cell death and control of cell survival in the oligodendrocyte lineage. Cell 1992; 70: 31-46.
94. Arenas E, Persson H. Neurotrophin-3 prevents the death of adult central noradrenergic neurons in vivo. Nature 1994; 367: 368-371.
95. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn Superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
96. Rao VR, Cohen GB, Oprian DD. Rhodopsin mutation G90D and a molecular mechanism for congenital night-blindness. Nature 1994; 367: 639-642.
97. Woo D. Apoptosis and loss of renal tissue in polycystic kidney diseases. New Engl J Med 1995; 333: 18-25.
98. Goldin RD, Hunt NC, Clark J, Wickramassinghe SN. Apoptotic bodies in a murine model of alcoholic liver disease: reversibility of ethanol-induced changes. J Pathol 1993; 171: 73-76.
99. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994; 94: 1621-1628.
100. Han DKM, Haudenschild CC, Hong MK, Tinkle BT, Leon MB, Liau G. Evidence for apoptosis in human atherogenesis and in rat vascular injury model. Am J Pathol 1995; 147: 267-277.
101. Geng YJ, Libby P. Evidence for apoptosis in advanced human atheroma: co-localization with interleukin-1β converting enzyme. Am J Pathol 1995; 147: 251-266.
102. Whyte MKB, Meagher LC, MacDermot J, Haslett C. Impairment of function in aging neutrophils is associated with apoptosis. J Immunol 1993; 150: 5124-5134.
103. Lockshin RA, Zackeri ZF. Programmed cell death: new thoughts and relevance to aging. J Gerontol 1990; 45: 135-140.
104. Zhou T, Edwards CK 3rd, Mountz JD. Prevention of age-related T-cell apoptosis defect in CD2-Fas-transgenic mice. J Exp Med 1995; 182: 129-137.
105. Hodes RJ. Molecular alterations in the aging immune system. J Exp Med 1995; 182: 1-3.
106. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface blebs on apoptotic keratinocytes. J Exp Med 1994; 179: 1317-1330.
107. Szende B, Romics I, Vass L. Apoptosis in prostate cancer after hormonal treatment. Lancet 1993; 342: 1422.
108. Levine EL, Davidson SE, Roberts SA, Chadwick CA, Potten CS, West CM. Apoptosis as predictor to radiotherapy in cervical carcinoma. Lancet 1994; 344: 472.
109. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA: implications for the treatment of Parkinson's disease. J Clin Invest 1995; 95: 2458-2464.
110. Bertrand R, Solary E, Jenkins J, Pommier Y. Apoptosis and its modulation in human promyelocytic HL-60 cells treated with topoisomerase I and II inhibitors. Exp Cell Res 1993; 207: 388-397.
111. Brown DG, Sun XM, Cohen CM. Dexamethasone-induced apoptosis involves cleavage of DNA to large fragments prior to internucleosomal fragmentation. J Biol Chem 1993; 268: 3037-3039.
112. Jacobson MD, Burne JF, Raff MC. Programmed cell death and Bcl-2 protection in the absence of a nucleus. EMBO J 1994; 13: 1899-1910.
113. Nakajima H, Goldstein P, Henkart PA. The target cell nucleus is not required for cell-mediated granzyme or Fas-based cytotoxicity. J Exp Med 1995; 181: 1905-1909.
114. Bertrand B, Kohn KW, Solary E, Pommier Y. Detection of apoptosis-associated DNA fragmentation using a rapid and quantitative filter binding assay. Drug Dev Res 1995; 34: 138-144.
115. McGowan AJ, Fernandes RS, Verhaegen S, Cotter TG. Zinc inhibits UV radiation-induced apoptosis but fails to prevent subsequent cell death. Int J Rad Biol 1994; 66: 343-349.
116. Wang L, Miura M, Bergeron L, Zhu H, Yuan J. Ich-1, an ICE/ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Cell 1994; 78: 739-750.
117. Alnemri ES, Fernandez-Alnemri T, Litwack G. Cloning and expression of four novel isoforms of human interleukin-1 beta converting enzyme with different apoptotic activities. J Biol Chem 1995; 270: 4312-4317.
118. Dubrez L, Goldwasser F, Genne P, Pommier Y, Solary E. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 1995; 9: 1013-1024.
119. Pommier Y, Leteurtre F, Fesen M, et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 1994; 12: 530-542.
120. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J. Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase H-induced DNA strand breaks ant their repair. Cancer Res 1993; 53: 4251.
121. Campos L, Rouault JP, Sabido O, et al. High expression of Bcl-2 protein in acute myeloblastic leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091-3096.
122. Kondo S, Yin D, Takeuchi J, Morimura T, Oda Y, Kikuchi H. bcl-2 gene enables rescue from in vitro myelosuppression (bone marrow cell death) induced by chemotherapy. Br J Cancer 1994; 70: 421-426.
123. Campos L, Sabido O, Rouault JP, Guyotat D. Effects of Bcl-2 antisense oligonucleotides on in vitro proliferation and survival of normal bone marrow progenitors and leukemic cells. Blood 1994; 84: 595-600.
124. de Fabritiis P, Amadori S, Calabretta B, Mandelli F. Elimination of clonogenic Philadelphia positive cells using BCR-ABL antisense oligonucleotides. Bone Marrow Transpl 1993; 12: 261-265.
125. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993; 75: 229-240.
126. Motoyama N, Wang F, Roth KA, et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 1995; 267: 1506-1510.
127. Levy Y, Brouet JC. Interleukin-10 prevents spontaneous death of germinal center B-cells by induction of the Bcl-2 protein. J Clin Invest 1994; 93: 424-428.
128. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin-4 protects chronic lymphocytic leukemic B-cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992; 176: 1319-1326.
129. Sarin A, Clerici M, Blatt SP, Hendrix CW, Shearer GM, Henkart PA. Inhibition of activation-induced programmed cell death and restoration of defective immune responses of HIV+ donors by cysteine protease inhibitors. J Immunol 1994; 153: 862-872.
130. Squier MKT, Miller ACK, Malkinson AM, Cohen JJ. Calpain activation in apoptosis. J Cell Physiol 1994; 159: 229-237.
131. Wright SC, Wei QS, Zhong J, Zheng H, Kinder DH, Larrick JW. Purification of a 24 kD protease from apoptotic tumor cells that activate DNA fragmentation. J Exp Med 1994; 180: 2113-2123.
132. Irmler M, Hertig S, MacDonald HR, et al. Granzyme A is an interleukin-1 beta converting enzyme. J Exp Med 1995; 181: 1917-1922.
133. Staal FJT, Anderson MT, Staal GEJ, Herzenberg LA, Gitler C, Herzenberg LA. Redox regulation of signal transduction: tyrosine phosphorylation and calcium influx. Proc Natl Acad Sci USA 1994; 91: 3169-3122.
134. Dröge W, Eck HP, Mihm S. HIV-induced cysteine deficiency and T-cell dysfunction: a rationale for treatment with N-acetylcysteine. Immunol Today 1992; 13: 211-214.
135. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78: 539-542.
136. Horio Y, Takahashi T, Kuroishi T, et al. Prognostic significance of p53 deletions in primary resected non-small cell lung cancer. Cancer Res 1993; 53: 1-4.
137. Elrouby S, Thomas A, Costin D, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of mdr1/mdr3 gene expression. Blood 1993; 82: 3452-3459.
138. Lowe SC, Bodis S, McClatchey, et al. P53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-810.
139. Critchfield JM, Racke MK, Zuniga-Pflücker JC, et al. T-cell deletion in high antigen dose therapy of autoimmune encephalitis. Science 1994; 263: 1139-1143.
140. Pulendran B, Kannourakis G, Nouri S, Smith KGC, Nossal GJV. Soluble antigen can cause enhanced apoptosis of germinal-centre B-cells. Nature 1995; 375: 331-334.
141. Shokat KM, Goodnow CC. Antigen-induced B-cell death and elimination during germinal centre immune response. Nature 1995; 375: 334-338.
142. Deftos M, Olee T, Carson DA, Chen PP. Defining the genetic origins of three rheumatoid synovium-derived IgG rheumatoid factors. J Clin Invest 1994; 93: 2525-2553.
143. Nicolle NW, Nag B, Sharma SD, et al. Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes. J Clin Invest 1994; 93: 1361-1369.
144. Kobayashi N, Hamamoto Y, Yamùamoto N, Ishii A, Yonehara M, Yonehara S. Anti-Fas monoclonal antibody is cytocidal to human immunodeficiency virus-infected cells without augmenting viral replication. Proc Natl Acad Sci USA 1990; 87: 9620-9624.
145. Debatin KM, Goldman CK, Waldmann TA, Krammer PH. APO-1 induced apoptosis of leukemia cells from patients with adult T-cell leukemia. Blood 1993; 81: 2972-2977.
146. Morimoto H, Yonehara S, Bonavida B. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res 1993; 53: 2591-2596.
147. Neta R, Stiefel SM, Finkelman F, Herrmann S, Ali N. IL-12 protects bone marrow from and sensitizes intestinal tract to ionizing radiations. J Immunol 1994; 153: 4230-4237.
148. Löwenberg B, Touw P. Hematopoietic growth factors and their receptors in acute leukemia. Blood 1993; 81: 281-292.
149. Lotem J, Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor-ß and cancer chemotherapy compounds in myeloid leukemic cells. Blood 1992; 80: 1750-1757.
150. Estey E, Thall PF, Kantarjian H, et al. Treatment of newly diagnosed acute myelognous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 1992; 79: 2246-2255.
151. Colombel M, Olsson CA. Hormone-regulated apoptosis results from re-entry of differentiated prostate cells onto a defective cell cycle. Cancer Res 1992; 52: 4313-4319.
152. Lunardi-Iskandar Y, Bryant JL, Zeman RA, et al. Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature 1995; 375: 64-68.